Device Trial Radar · NCT07700147
Evaluation of an Electric Stimulator for Medical Use by Personal (LRTPM1) for Visual Function in Early to Intermediate Dry Age-Related Macular Degeneration
Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Jul 9, 2026
Primary completion
Dec 9, 2027
Study completion Apr 17, 2028
Sponsor
- Lead sponsor
- Nu Eyne Co., Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 13, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the efficacy and safety of an electric stimulator for medical use by personal (LRTPM1) in patients with early to intermediate dry age-related macular degeneration. The main questions this study aims to answer are: * Does the investigational device improve visual function, as assessed by best corrected visual acuity and contrast sensitivity? * What treatment-emergent adverse events occur during the study? Participants will: * Be randomized to receive either active stimulation or sham stimulation * Apply the assigned investigational device at home once daily for 30 minutes over a 12-week treatment period * Visit the study site for eye examinations and safety assessments * Return for a follow-up visit 4 weeks after the end of treatment
Conditions
- Dry Age-Related Macular Degeneration
- AMD
Interventions
Transcutaneous Electrical StimulationDevice
The active intervention uses transcutaneous electrical stimulation (TES) delivered by the investigational personal-use electric stimulator (LRTPM1). Electrodes are attached to the ocular and periocular area, and the device delivers pulsed electrical stimulation. Participants will apply the assigned device once daily for 30 minutes over a 12-week treatment period.
Sham Transcutaneous Electrical StimulationDevice
The sham device is identical in appearance to the active investigational device but does not provide active electrical stimulation. Participants will apply the assigned sham device once daily for 30 minutes over a 12-week treatment period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Best Corrected Visual Acuity (BCVA) Measured by ETDRS Letter ScoreTime frame: Baseline, Week 2, Week 6, Week 12, Week 16
1 more outcomes with a free account
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Asan Medical Center
Seoul, South Korea
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.